Seeking Alpha

Affymax (AFFY +41.3%) skyrockets following yesterday's recommendation by an FDA advisory panel...

Affymax (AFFY +41.3%) skyrockets following yesterday's recommendation by an FDA advisory panel for its peginesatide treatment of anemia in dialysis patients. Cowen believes the drug can capture $250M in U.S. sales by 2016, and Raymond James suspects AFFY can take market share if it prices its drug lower than Amgen's (AMGN +1%) Epogen.
Comments (0)
Be the first to comment
DJIA (DIA) S&P 500 (SPY)